Roche Holding AG (XSWX:ROP) EBIT: CHF18,319 Mil (TTM As of Dec. 2025)


XSWX:ROP Roche Holding AG XSWX:ROP
79 GF Score
Price CHF332.00
GF Value CHF264.69
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Roche Holding AG EBIT?

Roche Holding AG XSWX:ROP +2.09% 79 EBIT is CHF18,319 Mil as of Dec. 2025. GuruFocus rates XSWX:ROP with a GF Score™ of 79/100 and a GF Value™ of CHF264.69 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Roche Holding AG's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was CHF8,039 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF18,319 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Roche Holding AG's annualized ROC % for the quarter that ended in Dec. 2025 was 16.42%. Roche Holding AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 66.34%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Roche Holding AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 6.39%.


Roche Holding AG  (XSWX:ROP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Roche Holding AG's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=16292 * ( 1 - 19.2% )/( (79320 + 81067)/ 2 )
=13163.936/80193.5
=16.42 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Roche Holding AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=16078/( ( (22874 + max(2663, 0)) + (22934 + max(-1928, 0)) )/ 2 )
=16078/( ( 25537 + 22934 )/ 2 )
=16078/24235.5
=66.34 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(11918 + 7597 + 4161) - (7323 + 0 + 13690)
=2663

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(12391 + 7479 + 1686) - (8908 + 0 + 14576)
=-1928

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Roche Holding AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=18319/286727.569
=6.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Roche Holding AG EBIT Related Terms


Roche Holding AG EBIT Historical Data

* Premium members only.

The historical data trend for Roche Holding AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roche Holding AG EBIT Chart

Roche Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17,817.00 17,017.00 15,076.00 13,196.00 18,319.00

Roche Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,413.00 8,929.00 4,267.00 10,280.00 8,039.00

XSWX:ROP vs LLY, JNJ, ABBV: EBIT Comparison

For the Drug Manufacturers - General subindustry, Roche Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roche Holding AG EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's EV-to-EBIT falls into.


XSWX:ROP
79GF Score
Roche Holding AG XSWX:ROP
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roche Holding AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF18,319 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of CHF18,319 Mil mean?
Roche Holding AG (XSWX:ROP) has a EBIT of CHF18,319 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Roche Holding AG.
Is Roche Holding AG's EBIT too high?
Roche Holding AG's current EBIT is CHF18,319 Mil. Overall, Roche Holding AG has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's EBIT compare to LLY and JNJ?
Roche Holding AG's EBIT of CHF18,319 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Roche Holding AG. Roche Holding AG's current EBIT is CHF18,319 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:ROP) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF264.69, compared to a current price of CHF332.00 — trading 25.4% above its estimated fair value. The current EBIT is CHF18,319 Mil. Roche Holding AG's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Roche Holding AG (XSWX:ROP), the current EBIT is CHF18,319 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roche Holding AG (XSWX:ROP) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of CHF332.00 is trading 25.4% above its estimated GF Value™ of CHF264.69. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for XSWX:ROP:

  • EBIT: CHF18,319 Mil
  • GF Value™: CHF264.69 vs. price of CHF332.00 (25.4% above fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the XSWX:ROP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
79GF Score

Get the complete analysis for XSWX:ROP

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF332.00
Price
CHF264.69
GF Value